Dobutamine echocardiography predicts functional outcome after revascularisation in patients with dysfunctional myocardium irrespective of the perfusion pattern on resting thallium-201 imaging

Efficacy of noninvasive cardiac imaging tests in diagnosis and management of stable coronary artery disease

The aim of this review was to discuss the current literature regarding the utility of noninvasive imaging in diagnosis and management of stable coronary artery disease (CAD) including recent data from large randomized trials assessing diagnosis and prognosis. Current guidelines recommend revascularization in patients with refractory angina and in those with potential prognostic benefit. Appropriate risk stratification through noninvasive assessment is important in ensuring patients are not exposed to unnecessary invasive coronary angiograms. The past 20 years have seen an unprecedented expansion in noninvasive imaging modalities for the assessment of stable CAD, with cardiovascular magnetic resonance and computed tomography complementing established techniques such as myocardial perfusion imaging, echocardiography and exercise electrocardiogram. In this review, we examine the current state-of-the-art in noninvasive imaging to provide an up-to-date analysis of current investigation and management options.

Prognostic validation of an algorithm to convert myocardial perfusion SPECT imaging data from a 12-segment model to a 17-segment model

BACKGROUND

A 17-segment model has become the standard for interpreting myocardial perfusion single-photon emission computed tomography (SPECT). Methods for converting pre-existing databases from 12-segment models to the 17-segment model are needed for ongoing prognostic studies.

METHODS AND RESULTS

To develop the conversion algorithm, 150 consecutive SPECT studies (82 abnormal) were read by both a 12-segment and the standard 17-segment models. Summed stress scores (SSSs) were calculated from a 17-segment model derived from the 12-segment data and compared to those of the standard 17-segment model. The effect of the conversion algorithm on prognostic data derived from the 12-segment model was evaluated in 25,876 patients from the Duke Nuclear Cardiology Database, including a sample of 3,205 patients with known covariates for adjusted analysis. The derived 17-segment SSS from the 12-segment model was highly correlated (R = 0.99) to the SSS from the standard 17-segment model. In both unadjusted and adjusted analysis, there was no difference in the prognostic information.

CONCLUSIONS

An algorithm for conversion of 12-segment perfusion scores to 17-segment scores has been developed which is highly correlated to visual interpretation by the 17-segment model with nearly identical prognostic information.

Diagnostic and imaging considerations: role of viability

Left ventricular systolic dysfunction is a recognised feature of heart failure. In developed nations, the leading cause of left ventricular systolic dysfunction is coronary artery disease. Revascularisation is a treatment strategy for patients with predominant symptoms of heart failure and significant left ventricular dysfunction. Presence or absence of myocardial viability has been shown to affect outcome after revascularisation. There are various techniques to assess myocardial viability. However, limitations of current literature, lack of completed randomised trials and high peri-procedural trials create significant uncertainty about the optimal strategy. This review focuses on the role of non-invasive testing for myocardial viability in patients with left ventricular systolic dysfunction and heart failure and also outlines the pros and cons of each technique.

Stress echocardiography for the diagnosis and risk stratification of patients with suspected or known coronary artery disease: a critical appraisal. Supported by the British Society of Echocardiography

Stress echocardiography today has matured into a robust and reliable technique not only for the diagnosis of suspected coronary artery disease (CAD) but also for the accurate risk stratification of patients with suspected and established CAD. This is mainly because of rapid advances in image acquisition, digital display, and the development of harmonic and contrast imaging. Stress echocardiography today is also utilised in patients with heart failure both for assessing the cause of heart failure and determining the extent of hibernating myocardium. With advances in myocardial perfusion imaging, stress echocardiography now allows simultaneous assessment of myocardial function and perfusion. Tissue Doppler imaging allows quantitation of wall motion. Ready availability and reliability makes stress echocardiography a cost effective technique for the assessment of CAD.

Does resting two-dimensional echocardiography identify patients with ischemic cardiomyopathy and low likelihood of functional recovery after coronary revascularization?

OBJECTIVE

To evaluate the potential of a simple and widely available technique as two-dimensional (2D) echocardiography to identify patients with ischemic cardiomyopathy and low likelihood of functional recovery after coronary revascularization.

METHODS

Two-dimensional echocardiography and radionuclide ventriculography (RNV) were performed before coronary revascularization in 94 patients with ischemic cardiomyopathy. Left ventricular ejection fraction (LVEF) was measured by RNV. Regional wall motion abnormalities, wall motion score index, end-diastolic wall thickness (EDWT), left ventricular (LV) volumes and LV sphericity index were assessed in the echocardiographic images. RNV was repeated 9-12 months after revascularization to assess LVEF change; an improvement >or=5% was considered clinically significant.

RESULTS

Nine hundred and ninety-nine segments were severely dysfunctional; 149 out of 999 (15%) had an EDWT <or=6 mm. A severe enlargement of the end-diastolic volume index (EDVI) (>or=100 ml/ml) and of the end-systolic volume index (>or=80 ml) was present in 32 (34%) and 21 (22%) patients, respectively. A spherical shape of the LV was observed in 35 (37%) patients. LVEF after revascularization increased in 30 out of 94 patients (32%) from 30+/-8% to 39+/-9% (P<0.0001). On multivariate analysis, the EDVI was the only predictor of no recovery in LVEF [odds ratio, 1.06, confidence interval (CI), 1.04-1.1, P<0.0001]. The cut-off value of EDVI >or=90 ml/ml accurately identified patients that virtually never recover. Post-operatively, LVEF increased in three out of 42 (7%, 95% CI 0-15%) patients with EDVI >or=90 ml/ml as compared to 27 out of 52 (52%) patients with EDVI<90 ml/ml (P<0.0001).

CONCLUSIONS

In patients with ischemic cardiomyopathy and severe LV enlargement, improvement of LVEF after revascularization is unlikely to occur. Conversely, in patients with relatively preserved LV size, a higher likelihood of functional recovery may be anticipated.

Myocardial contrast echocardiography in acute coronary syndromes

MCE is a reliable, bedside technique for assessment of a patient with acute coronary syndrome. It can be used to estimate the myocardial risk-area and infarct size and to establish peri-infarct viability. This information is critical in both management decision-making and in assigning prognosis in the setting of acute coronary syndromes.

The heart failure revascularisation trial (HEART): rationale, design and methodology

BACKGROUND

Most patients with heart failure due to left ventricular systolic dysfunction (LVSD) secondary to coronary artery disease (CAD) have evidence of myocardium in jeopardy (reversible ischaemia and/or stunning hibernation). It is not known whether revascularisation in such cases is safe or beneficial.

AIMS

To determine whether revascularisation will improve the survival of patients with LVSD and heart failure secondary to CAD and myocardium in jeopardy.

METHODS

This is a randomised controlled trial comparing revascularisation or not, in addition to optimal medical therapy with ACE inhibitors, beta-blockers, aldosterone antagonists and an anti-thrombotic agent. Patients must have heart failure requiring treatment with diuretics, a left ventricular ejection fraction <35% and evidence of coronary disease. Myocardial viability and ischaemia are assessed by a broad range of techniques including stress echocardiography and nuclear imaging. All imaging tests are reviewed in core laboratories to ensure uniform reporting. Any conventional revascularisation technique is permitted. The primary outcome measure is all cause mortality. Symptoms, quality of life and health economic issues will also be explored. Assuming an annual mortality of 10% in the control group and allowing for substantial cross-over rates, a study of 800 patients followed for 5 years has 80% power with an alpha of 0.05 (two-sided) to show a 25% reduction in mortality with revascularisation.

RESULTS

At the time of writing 180 patients have been screened for inclusion, 111 have consented to participate and 70 have been randomised. The results of viability testing are awaited in 22 patients. Twenty-six patients had been investigated for myocardial viability and/or by angiography prior to consent, as part of the routine practice in that cardiology department. Of 68 patients who have completed assessment only after consent, 47 (69%) were included. The principal reason for drop-out between consent and randomisation was lack of evidence of myocardial ischaemia or hibernation.

CONCLUSION

The HEART trial will help to determine whether investigation of myocardial ischaemia and/or viability with a view to revascularisation should become part of the routine care of patients with heart failure due to LVSD and CAD.

The non-invasive assessment of hibernating myocardium in ischaemic cardiomyopathy--a myriad of techniques

Heart failure is placing an ever-increasing burden on society. Many subjects with heart failure and underlying coronary artery disease have a significant amount of akinetic but viable myocardium that is able to contract should myocardial perfusion improve (hibernating myocardium). Non-randomised studies have shown prognostic benefit in subjects with hibernating myocardium undergoing revascularisation. Several non-invasive techniques have been developed to assess the presence or absence of hibernating myocardium. This review will examine the epidemiology and underlying pathogenesis of hibernating myocardium; evaluate the non-invasive techniques for diagnosing hibernating myocardium, and look at therapeutic intervention in subjects with hibernating myocardium.

Dobutamine stress echocardiography for the detection of myocardial viability in patients with left ventricular dysfunction taking beta blockers: accuracy and optimal dose

OBJECTIVE

To assess the accuracy of dobutamine stress echocardiography (DSE) and the optimal dose of dobutamine to detect myocardial viability in patients with ischaemic left ventricular (LV) dysfunction who are taking beta blockers, using the recovery of function six months artery revascularisation as the benchmark.

PATIENTS

17 patients with ischaemic LV dysfunction (ejection fraction < 40%) and chronic treatment with beta blockers scheduled to undergo surgical revascularisation.

SETTING

Regional cardiothoracic centre.

METHODS

All patients underwent DSE one week before and resting echocardiography six months after revascularisation. A wall motion score was assigned to each segment for each dobutamine infusion stage, using the standard 16 segment model of the left ventricle. The accuracy of DSE to predict recovery of resting segmental function was calculated for low dose (5 and 10 microg/kg/min) and for a full protocol of dobutamine infusion (5 to 40 microg/kg/min).

RESULTS

Of the 272 segments studied, 158 (58%) were dysfunctional at rest, of which 79 (50%) improved at DSE and 74 (47%) recovered resting function after revascularisation. Analysis of results with a low dose showed a significantly lower sensitivity and negative predictive value than with a full protocol (47% v 81%, p < 0.001 and 65% v 82%, p < 0.05, respectively). The accuracy in the full protocol analysis was comparable with that reported in patients no longer taking beta blockers but was significantly lower than that in the low dose analysis (78% v 66%, p < 0.001).

CONCLUSIONS

Findings suggest that beta blocker withdrawal is not necessary before DSE when viability is the clinical information in question. However, a completed protocol with continuous image recording is required to detect the full extent of viability.

Role of dobutamine echocardiography in detection of myocardial viability for predicting outcome after revascularization in ischemic cardiomyopathy

Coronary artery disease is the most common cause of heart failure in the Western world. Compared with medical therapy, surgical revascularization has been shown to improve survival rates in nonrandomized trials in patients with ischemic cardiomyopathy. However, perioperative mortality is high in this group of patients who do not demonstrate significant viable myocardium. Echocardiography during dobutamine infusion has been shown to reliably detect viable myocardium. Several studies have demonstrated its ability to provide high predictive value for recovery of both regional and global left ventricular function after revascularization. Indeed, nonrandomized studies also have indicated its value in predicting which patients with severe ischemic cardiomyopathy are likely to survive after revascularization. Dobutamine stress echocardiography has emerged as a safe and valuable technique for the assessment of myocardial viability and for the selection of patients for revascularization.

Value of dobutamine echocardiography for the assessment of myocardial viability for revascularization

Coronary artery disease accounts for a majority of heart failure cases in the western world. Many cardiologists believe that abnormal regional contractions in patients with coronary artery disease is equivalent to irreversibly damaged myocardium. Studies now challenge this long-held assumption. Data exist regarding the value of assessing myocardial viability in those patients with severe left ventricular dysfunction and coronary artery disease. This report discusses dobutamine echocardiography as a technique for assessing myocardial viability and for selecting patients for revascularization. (c)2001 by CHF, Inc.

Dobutamine stress electrocardiography-gated Tc-99m tetrofosmin SPECT for detection of viable but dysfunctional myocardium

BACKGROUND

Technetium-99m-labeled myocardial perfusion tracers allow simultaneous assessment of myocardial perfusion and left ventricular function by electrocardiography-gated scan. This study was performed to determine whether dobutamine stress electrocardiography-gated tetrofosmin single photon emission computed tomography (SPECT) can identify viable (as defined by positron emission tomography [PET]) but dysfunctional myocardium with contractile reserve.

METHODS AND RESULTS

Thirty-five patients with myocardial infarction underwent resting electrocardiography-gated SPECT and fluorodeoxyglucose (FDG) PET. The relative uptakes of tetrofosmin (%tetrofosmin) and FDG (%FDG) were calculated. Wall motion in 9 left ventricular segments was assessed at rest and during dobutamine stress on a 3-dimensional cine-mode display created with automatic left ventricular function analysis software. A total of 129 dysfunctional segments were analyzed. Forty-five (48.9%) of 92 segments with %tetrofosmin of 50% or greater and only 4 (10.8%) of 37 segments with %tetrofosmin less than 50% had contractile reserves (P <.0001). The sensitivity, specificity, and predictive accuracy of %tetrofosmin of 50% or greater for detecting %FDG of 50% or greater were 85.7%, 74%, and 82.9%, respectively. The incidence of the presence of contractile reserve rose with increasing magnitude of %FDG. The sensitivity, specificity, and predictive accuracy of the presence of contractile reserve for detecting %FDG of 50% or greater were 43.9%, 80.6%, and 52.7%, respectively.

CONCLUSIONS

Dobutamine stress electrocardiography-gated SPECT can identify viable (as defined by PET) but dysfunctional myocardium with contractile reserve.